Vanguard Group Inc. Acquires 279,379 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Vanguard Group Inc. increased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 2.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,591,043 shares of the company's stock after buying an additional 279,379 shares during the period. Vanguard Group Inc. owned 11.63% of Myriad Genetics worth $145,203,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in MYGN. Disciplined Growth Investors Inc. MN boosted its holdings in Myriad Genetics by 21.1% in the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company's stock worth $69,226,000 after acquiring an additional 440,107 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Myriad Genetics by 377.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 549,456 shares of the company's stock worth $7,533,000 after purchasing an additional 434,420 shares during the last quarter. State Street Corp boosted its stake in Myriad Genetics by 8.3% in the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company's stock worth $128,827,000 after purchasing an additional 359,685 shares in the last quarter. Fisher Asset Management LLC grew its position in Myriad Genetics by 50.2% during the 4th quarter. Fisher Asset Management LLC now owns 905,209 shares of the company's stock valued at $12,410,000 after purchasing an additional 302,367 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in Myriad Genetics by 117.0% during the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company's stock valued at $4,548,000 after purchasing an additional 179,527 shares in the last quarter. Hedge funds and other institutional investors own 99.02% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on MYGN shares. Raymond James reiterated an "outperform" rating and set a $19.00 price target (down previously from $27.00) on shares of Myriad Genetics in a report on Tuesday, February 25th. Bank of America lowered their target price on Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating on the stock in a report on Monday, March 3rd. StockNews.com upgraded shares of Myriad Genetics from a "hold" rating to a "buy" rating in a research note on Thursday. The Goldman Sachs Group decreased their price objective on shares of Myriad Genetics from $29.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Finally, UBS Group decreased their price target on Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a report on Tuesday, February 25th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Myriad Genetics presently has an average rating of "Hold" and an average price target of $20.89.

Myriad Genetics Price Performance

Shares of Myriad Genetics stock traded up $0.05 during trading hours on Friday, reaching $8.00. The company's stock had a trading volume of 777,082 shares, compared to its average volume of 899,654. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics, Inc. has a one year low of $7.35 and a one year high of $29.30. The firm has a 50 day moving average price of $10.71 and a 200-day moving average price of $14.98. The stock has a market cap of $730.47 million, a P/E ratio of -6.15 and a beta of 1.87.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million during the quarter, compared to analysts' expectations of $210.35 million. During the same quarter last year, the firm posted ($0.12) EPS. On average, analysts predict that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.